Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Moderna, Inc. stock logo
MRNA
Moderna
$26.25
-1.8%
$25.88
$23.15
$58.62
$10.44B2.0110.87 million shs7.03 million shs
Ocugen, Inc. stock logo
OCGN
Ocugen
$1.63
+1.9%
$1.27
$0.52
$1.90
$467.69M4.28.39 million shs6.73 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$24.53
-0.8%
$24.88
$20.92
$29.82
$140.60B0.5563.65 million shs42.21 million shs
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
$1.60
-5.3%
$1.28
$0.35
$2.32
$1.86B1.98102.00 million shs75.10 million shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Moderna, Inc. stock logo
MRNA
Moderna
-1.83%-3.99%+11.65%-18.12%-54.53%
Ocugen, Inc. stock logo
OCGN
Ocugen
+1.87%-7.39%+52.34%+56.73%+71.60%
Pfizer Inc. stock logo
PFE
Pfizer
-0.77%-6.64%+2.57%-0.26%-15.66%
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
-5.33%-6.43%+42.86%+165.47%+0.63%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Moderna, Inc. stock logo
MRNA
Moderna
$26.25
-1.8%
$25.88
$23.15
$58.62
$10.44B2.0110.87 million shs7.03 million shs
Ocugen, Inc. stock logo
OCGN
Ocugen
$1.63
+1.9%
$1.27
$0.52
$1.90
$467.69M4.28.39 million shs6.73 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$24.53
-0.8%
$24.88
$20.92
$29.82
$140.60B0.5563.65 million shs42.21 million shs
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
$1.60
-5.3%
$1.28
$0.35
$2.32
$1.86B1.98102.00 million shs75.10 million shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Moderna, Inc. stock logo
MRNA
Moderna
-1.83%-3.99%+11.65%-18.12%-54.53%
Ocugen, Inc. stock logo
OCGN
Ocugen
+1.87%-7.39%+52.34%+56.73%+71.60%
Pfizer Inc. stock logo
PFE
Pfizer
-0.77%-6.64%+2.57%-0.26%-15.66%
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
-5.33%-6.43%+42.86%+165.47%+0.63%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Moderna, Inc. stock logo
MRNA
Moderna
2.00
Hold$40.9355.94% Upside
Ocugen, Inc. stock logo
OCGN
Ocugen
2.33
Hold$7.00329.45% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.37
Hold$28.3515.61% Upside
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
2.00
Hold$2.0025.00% Upside

Current Analyst Ratings Breakdown

Latest OCGN, MRNA, PFE, and TLRY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/10/2025
Pfizer Inc. stock logo
PFE
Pfizer
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetEqual Weight$33.00 ➝ $32.00
10/10/2025
Moderna, Inc. stock logo
MRNA
Moderna
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetEqual Weight$31.00 ➝ $32.00
10/9/2025
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
Atb Cap Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHoldStrong Sell
10/8/2025
Moderna, Inc. stock logo
MRNA
Moderna
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
10/8/2025
Ocugen, Inc. stock logo
OCGN
Ocugen
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
10/8/2025
Pfizer Inc. stock logo
PFE
Pfizer
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C-)
10/8/2025
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
10/3/2025
Pfizer Inc. stock logo
PFE
Pfizer
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$28.00 ➝ $30.00
10/1/2025
Pfizer Inc. stock logo
PFE
Pfizer
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral$28.00
9/27/2025
Moderna, Inc. stock logo
MRNA
Moderna
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
9/27/2025
Ocugen, Inc. stock logo
OCGN
Ocugen
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 10/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Moderna, Inc. stock logo
MRNA
Moderna
$3.24B3.17N/AN/A$28.33 per share0.93
Ocugen, Inc. stock logo
OCGN
Ocugen
$4.05M117.64N/AN/A$0.10 per share16.30
Pfizer Inc. stock logo
PFE
Pfizer
$63.83B2.18$4.33 per share5.67$15.62 per share1.57
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
$821.31M2.14$0.14 per share11.69$1.38 per share1.16
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Moderna, Inc. stock logo
MRNA
Moderna
-$3.56B-$7.53N/AN/AN/A-94.31%-25.96%-20.09%11/6/2025 (Estimated)
Ocugen, Inc. stock logo
OCGN
Ocugen
-$54.05M-$0.20N/AN/AN/A-1,197.71%-255.25%-86.79%11/13/2025 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$8.03B$1.8813.058.090.8216.84%21.42%9.12%11/4/2025 (Estimated)
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
-$2.19B-$2.27N/AN/AN/A-258.54%-6.79%-5.30%N/A

Latest OCGN, MRNA, PFE, and TLRY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/6/2025Q3 2025
Moderna, Inc. stock logo
MRNA
Moderna
-$1.95N/AN/AN/A$893.29 millionN/A
11/4/2025Q3 2025
Pfizer Inc. stock logo
PFE
Pfizer
$0.79N/AN/AN/A$16.94 billionN/A
10/9/2025Q1 2026
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
-$0.03-$0.0002+$0.0298N/A$205.75 million$209.50 million
8/5/2025Q2 2025
Pfizer Inc. stock logo
PFE
Pfizer
$0.58$0.78+$0.20$0.51$13.43 billion$14.65 billion
8/1/2025Q2 2025
Moderna, Inc. stock logo
MRNA
Moderna
-$2.99-$2.13+$0.86-$2.13$116.26 million$142.00 million
8/1/2025Q2 2025
Ocugen, Inc. stock logo
OCGN
Ocugen
-$0.06-$0.05+$0.01-$0.05$0.35 million$1.37 million
7/28/2025Q4 2025
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
-$0.03$0.02+$0.05-$1.30$250.41 million$224.54 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Ocugen, Inc. stock logo
OCGN
Ocugen
N/AN/AN/AN/AN/A
Pfizer Inc. stock logo
PFE
Pfizer
$1.727.01%N/A91.49%16 Years
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
N/AN/AN/AN/AN/A

Latest OCGN, MRNA, PFE, and TLRY Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/9/2025
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.436.82%11/7/202511/7/202512/1/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Moderna, Inc. stock logo
MRNA
Moderna
N/A
3.93
3.77
Ocugen, Inc. stock logo
OCGN
Ocugen
9.18
1.83
1.83
Pfizer Inc. stock logo
PFE
Pfizer
0.65
1.16
0.85
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
0.15
2.62
1.56

Institutional Ownership

CompanyInstitutional Ownership
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
Ocugen, Inc. stock logo
OCGN
Ocugen
10.27%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
9.35%

Insider Ownership

CompanyInsider Ownership
Moderna, Inc. stock logo
MRNA
Moderna
11.00%
Ocugen, Inc. stock logo
OCGN
Ocugen
4.29%
Pfizer Inc. stock logo
PFE
Pfizer
0.06%
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
0.84%
CompanyEmployeesShares OutstandingFree FloatOptionable
Moderna, Inc. stock logo
MRNA
Moderna
5,800390.58 million347.62 millionOptionable
Ocugen, Inc. stock logo
OCGN
Ocugen
80292.30 million279.77 millionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
81,0005.69 billion5.68 billionOptionable
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
2,8421.10 billion1.09 billionOptionable

Recent News About These Companies

Tilray Brands (NASDAQ:TLRY) Trading Down 5.3% - Time to Sell?
Cannabis Stocks To Add to Your Watchlist - October 14th
Promising Cannabis Stocks To Watch Today - October 13th
Cannabis Stocks To Follow Now - October 12th
Cannabis Stocks To Consider - October 11th
Top 3 Canadian Cannabis Stocks to Watch in October 2025
Promising Cannabis Stocks To Follow Now - October 10th
Why Tilray Brands Stock Just Stubbed Out

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Moderna stock logo

Moderna NASDAQ:MRNA

$26.25 -0.49 (-1.83%)
Closing price 10/14/2025 04:00 PM Eastern
Extended Trading
$26.62 +0.37 (+1.41%)
As of 08:22 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Ocugen stock logo

Ocugen NASDAQ:OCGN

$1.63 +0.03 (+1.88%)
Closing price 10/14/2025 04:00 PM Eastern
Extended Trading
$1.68 +0.05 (+3.01%)
As of 08:21 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

Pfizer stock logo

Pfizer NYSE:PFE

$24.52 -0.21 (-0.83%)
Closing price 10/14/2025 03:59 PM Eastern
Extended Trading
$24.52 -0.01 (-0.04%)
As of 08:23 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Tilray Brands stock logo

Tilray Brands NASDAQ:TLRY

$1.60 -0.09 (-5.33%)
Closing price 10/14/2025 04:00 PM Eastern
Extended Trading
$1.66 +0.06 (+4.06%)
As of 08:22 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada.